Zoetis Inc (NYSE:ZTS) CEO Juan Ramon Alaix sold 135,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total value of $12,359,250.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NYSE:ZTS opened at $91.47 on Friday. The company has a market capitalization of $44.18 billion, a PE ratio of 37.94, a P/E/G ratio of 1.88 and a beta of 1.02. Zoetis Inc has a 1 year low of $60.44 and a 1 year high of $93.67. The company has a debt-to-equity ratio of 2.50, a current ratio of 4.38 and a quick ratio of 2.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.06. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.38 billion. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the company earned $0.53 EPS. research analysts expect that Zoetis Inc will post 3.07 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Zoetis by 6.7% during the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock worth $3,429,736,000 after acquiring an additional 2,584,199 shares during the last quarter. Polen Capital Management LLC lifted its stake in shares of Zoetis by 3.9% during the 2nd quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock worth $791,848,000 after acquiring an additional 351,447 shares during the last quarter. Brown Advisory Inc. lifted its stake in shares of Zoetis by 0.3% during the 1st quarter. Brown Advisory Inc. now owns 7,226,660 shares of the company’s stock worth $603,499,000 after acquiring an additional 19,546 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Zoetis by 9.1% during the 2nd quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock worth $543,099,000 after acquiring an additional 529,666 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Zoetis by 1.4% during the 1st quarter. Northern Trust Corp now owns 5,948,527 shares of the company’s stock worth $496,762,000 after acquiring an additional 82,183 shares during the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Several research firms have weighed in on ZTS. Argus raised their price target on Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a report on Tuesday. Stifel Nicolaus raised their price target on Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Morgan Stanley raised their price target on Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a report on Friday, August 3rd. BMO Capital Markets restated a “hold” rating and set a $82.00 price target on shares of Zoetis in a report on Thursday, August 2nd. Finally, Cantor Fitzgerald set a $98.00 price target on Zoetis and gave the company a “buy” rating in a report on Thursday, August 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $90.53.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.